Benzinga··Vandana SinghTakeda Stock Falls Despite Positive Pediatric UC Data for Entyvio
Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.
TAKPhase 3 trialpharmaceutical